Idorsia Ltd 0RQE.IL Stock
Idorsia Ltd Price Chart
Idorsia Ltd 0RQE.IL Financial and Trading Overview
| Idorsia Ltd stock price | 1.97 CHF |
| Previous Close | 8.02 CHF |
| Open | 7.98 CHF |
| Bid | 7.61 CHF x N/A |
| Ask | 8.41 CHF x N/A |
| Day's Range | 7.96 - 8.09 CHF |
| 52 Week Range | 7.42 - 17.8 CHF |
| Volume | 214.48K CHF |
| Avg. Volume | 105.42K CHF |
| Market Cap | 1.45B CHF |
| Beta (5Y Monthly) | 0.559386 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.57 CHF |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
0RQE.IL Valuation Measures
| Enterprise Value | 2.42B CHF |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 12.795941 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 21.406 |
| Enterprise Value/EBITDA | -3.072 |
Trading Information
Idorsia Ltd Stock Price History
| Beta (5Y Monthly) | 0.559386 |
| 52-Week Change | -40.49% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 17.8 CHF |
| 52 Week Low | 7.42 CHF |
| 50-Day Moving Average | 8.69 CHF |
| 200-Day Moving Average | 12.47 CHF |
0RQE.IL Share Statistics
| Avg. Volume (3 month) | 105.42K CHF |
| Avg. Daily Volume (10-Days) | 175.47K CHF |
| Shares Outstanding | 177.92M |
| Float | 109.65M |
| Short Ratio | N/A |
| % Held by Insiders | 36.03% |
| % Held by Institutions | 23.21% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -713.90% |
| Gross Margin | -243.89% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -51.55% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 112.94M CHF |
| Revenue Per Share (ttm) | 0.64 CHF |
| Quarterly Revenue Growth (yoy) | 305.69% |
| Gross Profit (ttm) | -292495000 CHF |
| EBITDA | -787105984 CHF |
| Net Income Avi to Common (ttm) | -842524032 CHF |
| Diluted EPS (ttm) | -4.52 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 220.02M CHF |
| Total Cash Per Share (mrq) | 1.24 CHF |
| Total Debt (mrq) | 1.23B CHF |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 2.259 |
| Book Value Per Share (mrq) | -4.835 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -871225984 CHF |
| Levered Free Cash Flow (ttm) | -560545984 CHF |
Profile of Idorsia Ltd
| Country | United Kingdom |
| State | N/A |
| City | Allschwil |
| Address | Hegenheimermattweg 91 |
| ZIP | 4123 |
| Phone | 41 58 844 10 10 |
| Website | https://www.idorsia.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Q&A For Idorsia Ltd Stock
What is a current 0RQE.IL stock price?
Idorsia Ltd 0RQE.IL stock price today per share is 1.97 CHF.
How to purchase Idorsia Ltd stock?
You can buy 0RQE.IL shares on the IOB exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Idorsia Ltd?
The stock symbol or ticker of Idorsia Ltd is 0RQE.IL.
Which industry does the Idorsia Ltd company belong to?
The Idorsia Ltd industry is Biotechnology.
How many shares does Idorsia Ltd have in circulation?
The max supply of Idorsia Ltd shares is 253.75M.
What is Idorsia Ltd Price to Earnings Ratio (PE Ratio)?
Idorsia Ltd PE Ratio is now.
What was Idorsia Ltd earnings per share over the trailing 12 months (TTM)?
Idorsia Ltd EPS is -4.57 CHF over the trailing 12 months.
Which sector does the Idorsia Ltd company belong to?
The Idorsia Ltd sector is Healthcare.